These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12529694)

  • 1. Clinical activity of arsenic trioxide in Burkitt-like lymphoma.
    Ravandi F; van Besien K
    Leukemia; 2003 Jan; 17(1):271-2. PubMed ID: 12529694
    [No Abstract]   [Full Text] [Related]  

  • 2. Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?
    Bachleitner-Hofmann T; Gisslinger B; Grumbeck E; Gisslinger H
    Br J Haematol; 2001 Mar; 112(3):783-6. PubMed ID: 11260084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Lo Coco F
    Haematologica; 2002 May; 87(5):452-3. PubMed ID: 12010655
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002.
    Dalton WS
    Clin Cancer Res; 2002 Dec; 8(12):3643-5. PubMed ID: 12473572
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical activity of arsenic trioxide for the treatment of multiple myeloma.
    Munshi NC; Tricot G; Desikan R; Badros A; Zangari M; Toor A; Morris C; Anaissie E; Barlogie B
    Leukemia; 2002 Sep; 16(9):1835-7. PubMed ID: 12200700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
    Hussein MA; Saleh M; Ravandi F; Mason J; Rifkin RM; Ellison R
    Br J Haematol; 2004 May; 125(4):470-6. PubMed ID: 15142117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
    Douer D; Tallman MS
    J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydrogen peroxide in the Burkitt's lymphoma cell line Raji provides protection against arsenic trioxide-induced apoptosis via the phosphoinositide-3 kinase signalling pathway.
    Lu D; Bai XC; Gui L; Su YC; Deng F; Liu B; Li XM; Zeng WS; Cheng BL; Luo SQ
    Br J Haematol; 2004 May; 125(4):512-20. PubMed ID: 15142122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.
    Litzow MR; Lee S; Bennett JM; Dewald GW; Gallagher RE; Jain V; Paietta EM; Racevskis J; Rousey SR; Mazza JJ; Tallman MS
    Haematologica; 2006 Aug; 91(8):1105-8. PubMed ID: 16870552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials referral resource. Clinical trials with arsenic trioxide.
    Murgo AJ; McBee WL; Cheson BD
    Oncology (Williston Park); 2000 Feb; 14(2):206, 211, 215-6 passim. PubMed ID: 10736809
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement.
    Zappasodi P; Rossi M; Ambaglio I; Bernasconi P; Corso A; Lazzarino M; Castagnola C
    Ann Hematol; 2011 May; 90(5):595-7. PubMed ID: 20721555
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
    Ammatuna E; Cavaliere A; Divona M; Amadori S; Scambia G; Lo-Coco F
    Br J Haematol; 2009 Aug; 146(3):341. PubMed ID: 19545283
    [No Abstract]   [Full Text] [Related]  

  • 13. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
    Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
    Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
    Sasaki M; Sugimoto K; Isobe Y; Oshimi K
    Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
    [No Abstract]   [Full Text] [Related]  

  • 16. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
    Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
    Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
    [No Abstract]   [Full Text] [Related]  

  • 17. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia.
    Mayorga J; Richardson-Hardin C; Dicke KA
    Clin J Oncol Nurs; 2002; 6(6):341-6. PubMed ID: 12434466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Selected mechanisms of the therapeutic effect of arsenic trioxide in cancer treatment].
    Izdebska M; Grzanka A; Szczepański MA; Litwiniec A
    Postepy Hig Med Dosw (Online); 2008 Sep; 62():463-7. PubMed ID: 18806735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide in acute promyelocytic leukemia: potion not poison.
    Powell BL
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1317-9. PubMed ID: 21929304
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparing two arsenic trioxide administration methods in APL therapy.
    Zhou J; Meng R; Yang BF
    Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.